Loading clinical trials...
Loading clinical trials...
A Phase 1, Open-Label, Single Dose Parallel-Group Study of Brensocatib Following a Single Oral Administration in Subjects With or Without Renal Impairment
Conditions
Interventions
Brensocatib
Locations
3
United States
USA002
Orlando, Florida, United States
USA003
Tampa, Florida, United States
USA001
San Antonio, Texas, United States
Start Date
July 20, 2021
Primary Completion Date
February 14, 2023
Completion Date
February 14, 2023
Last Updated
April 18, 2023
NCT07154901
NCT07165015
NCT06352411
NCT06835127
NCT07445906
NCT03289208
Lead Sponsor
Insmed Incorporated
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions